Biora soars as drug delivery device shows promise in colitis study

Biora Therapeutics

10/08/2022 15:00

** Shares of Biora Therapeutics Inc  BIOR.O  jump ~19% to 95
cents in early trade
    ** Co says its drug delivery device was well tolerated, and
performed as intended in a study on seven patients with
ulcerative colitis, which causes abdominal pain  urn:newsml:reuters.com:*:nGNX8ccMJh
    ** Adds the device accurately identified entry into the
large intestine, triggering release of a liquid payload, and
achieved distribution across the entire intestine
    ** The device was ingested orally by patients in single
dosage
    ** Including session gains, stock down 54.5% YTD

 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))